GENMAB A/S stock analysis

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic

Ticker: GMAB
Exchange: Nasdaq
Sector: Health Care
Industry: Pharmaceuticals

Market evidence and data freshness

The public preview recorded GENMAB A/S at 53.72 USD on 2026-11-05T19:12:55.000Z and marked the quote as delayed. This observation is not a trading signal.

Available price history spans 2026-05-11 through 2026-11-04 across 124 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

What should I review before buying GENMAB A/S stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

Inside the full analysis

Valuation
Growth
Financial health
Ownership
Research

Sign in to open the full analysis. Paid plans use included reports first, then your weekly usage limit. Access lasts 72 hours, including revisits.